Scarica l'app Stockscreener
17.14
6.33%
1.02
Dopo l'orario di chiusura:
17.20
0.06
+0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Immunovant Inc Borsa (IMVT) Ultime notizie
Visual analytics tools that track Immunovant Inc. performanceMarket Risk Report & Short-Term High Return Ideas - Newser
Real time breakdown of Immunovant Inc. stock performance2025 Historical Comparison & Smart Investment Allocation Tips - Newser
What are the analyst revisions for SWINIs Immunovant Inc. stock a good investment in YEARPortfolio Profit Report & Stepwise Trade Signal Implementation - خودرو بانک
What to do if you’re stuck in Immunovant Inc.Market Activity Summary & Expert Verified Stock Movement Alerts - Newser
Is Immunovant Inc. trending in predictive chart modelsWall Street Watch & Daily Stock Trend Watchlist - Newser
Real time social sentiment graph for Immunovant Inc.Trade Risk Report & Daily Stock Trend Reports - Newser
Is Immunovant Inc. a cyclical or defensive stockAnalyst Downgrade & Risk Adjusted Buy and Sell Alerts - خودرو بانک
Is Immunovant Inc. affected by consumer sentimentChart Signals & Advanced Technical Analysis Signals - خودرو بانک
Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating - MSN
What’s next for Immunovant Inc. stockWeekly Trend Summary & Trade Opportunity Analysis Reports - خودرو بانک
Is Immunovant Inc. stock good for income investors2025 Bull vs Bear & Accurate Intraday Trading Signals - خودرو بانک
Applying Elliott Wave Theory to Immunovant Inc.Analyst Upgrade & Technical Pattern Based Signals - Newser
Using data tools to time your Immunovant Inc. exitGlobal Markets & Risk Managed Investment Signals - Newser
Is Immunovant Inc. stock entering bullish territoryLayoff News & Community Verified Watchlist Alerts - Newser
Earnings visualization tools for Immunovant Inc.Market Activity Summary & Consistent Income Trade Recommendations - Newser
Immunovant Inc. stock outlook for YEARPortfolio Performance Summary & Safe Entry Trade Signal Reports - Newser
Risk vs reward if holding onto Immunovant Inc.Bond Market & Daily Technical Forecast Reports - Newser
Immunovant reports promising remission data for Graves’ disease therapy By Investing.com - Investing.com Australia
What is Immunovant Inc.’s book value per shareJuly 2025 Update & Daily Volume Surge Trade Alerts - خودرو بانک
Batoclimab data in Graves’ could signal bigger Immunovant win - BioWorld MedTech
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results - The Globe and Mail
Immunovant’s Batoclimab: A Game-Changer in the Evolving Graves’ Disease Market - AInvest
Momentum divergence signals in Immunovant Inc. chart2025 Buyback Activity & AI Enhanced Trading Alerts - Newser
Is Immunovant Inc. a strong growth stockMarket Volume Summary & Consistent Income Trade Recommendations - خودرو بانک
What machine learning models say about Immunovant Inc.2025 Market Trends & Verified Entry Point Detection - Newser
Immunovant stock rises as Oppenheimer reiterates Outperform on Graves’ data - Investing.com
What institutional flow reveals about Immunovant Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser
Combining price and volume data for Immunovant Inc.July 2025 Outlook & Reliable Intraday Trade Plans - Newser
Why Immunovant Stock Blasted Higher Today - AOL.com
Can momentum traders help lift Immunovant Inc.Portfolio Return Report & Verified Chart Pattern Trade Signals - Newser
Immunovant Reports 'Encouraging' Data on Graves' Disease Treatment; Shares Rise - MarketScreener
What to expect from Immunovant Inc. in the next 30 daysQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser
Immunovant Data for Batoclimab Shows Potential for Treating Uncontrolled Graves' Disease - MarketScreener
Immunovant Announces Promising Graves’ Disease Study Results - TipRanks
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients - The Manila Times
Immunovant reports promising remission data for Graves’ disease therapy - Investing.com
Immunovant Reports Promising Six-Month Off-Treatment Data for Batoclimab in Uncontrolled Graves' Disease Patients - Quiver Quantitative
Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy - Quiver Quantitative
80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study - Stock Titan
Intraday pattern recognizer results for Immunovant Inc.Market Activity Summary & Real-Time Stock Price Movement Reports - Newser
Using RSI to spot recovery in Immunovant Inc.M&A Rumor & Consistent Growth Stock Picks - Newser
Volume spikes in Immunovant Inc. stock – what they meanRisk Management & Advanced Technical Signal Analysis - Newser
How to use a screener to detect Immunovant Inc. breakoutsJuly 2025 Rallies & Stepwise Trade Signal Implementation - Newser
Immunovant Inc. stock volume spike explainedWeekly Gains Summary & Growth Oriented Trading Recommendations - Newser
Is now a turning point for Immunovant Inc.2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - Newser
What indicators show strength in Immunovant Inc.Quarterly Earnings Report & Weekly Watchlist for Hot Stocks - Newser
Using economic indicators to assess Immunovant Inc. potentialMarket Risk Report & Low Risk High Win Rate Stock Picks - Newser
Is Immunovant Inc. stock poised for growthMarket Movement Recap & Free Weekly Watchlist of Top Performers - Newser
Long term hold vs stop loss in Immunovant Inc.Layoff News & Expert Approved Momentum Trade Ideas - Newser
Short interest data insights for Immunovant Inc.July 2025 Patterns & Fast Entry and Exit Trade Plans - Newser
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):